A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

Part of paid clinical trials in Dallas, Texas.

Sponsor
Incyte Corporation
Study ID
NCT06416800
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Digoxin — DRUG
    Oral; Tablet
  • Rosuvastatin — DRUG
    Oral; Tablet
  • Metformin — DRUG
    Oral; Tablet
  • Povorcitinib — DRUG
    Oral; Tablet
  • Probenecid — DRUG
    Oral; Tablet

Study Details

The purpose of this study is to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants.

Key Dates

Start date
Jun 19, 2024
Status verified
Feb 2025
Primary completion
Jan 15, 2025
Completion
Jan 15, 2025

Study Design

Enrollment
71 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1: Dose
    Digoxin and povorcitinib will be administered at protocol defined doses.
  • Experimental: Cohort 2: Dose
    Rosuvastatin and povorcitinib will be administered at protocol defined doses.
  • Experimental: Cohort 3: Dose
    Metformin and povorcitinib will be administered at protocol defined doses.
  • Experimental: Cohort 4: Dose
    Probenecid and povorcitinib will be administered at protocol defined doses.

Primary Outcome Measure

Pharmacokinetic (PK) in plasma digoxin [ Time Frame: Up to Day 15 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research UnitDallasTexas75247-

Find similar trials in Dallas, TX

By research site
Fortrea Clinical Research Unit· Dallas, TX

Related Studies